170 related articles for article (PubMed ID: 11862346)
1. The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine.
de Jongh R; Groenink L; van Der Gugten J; Olivier B
Psychopharmacology (Berl); 2002 Jan; 159(2):176-80. PubMed ID: 11862346
[TBL] [Abstract][Full Text] [Related]
2. Protein synthesis and the mechanisms of lasting change in anxiety induced by severe stress.
Adamec R; Strasser K; Blundell J; Burton P; McKay DW
Behav Brain Res; 2006 Feb; 167(2):270-86. PubMed ID: 16256211
[TBL] [Abstract][Full Text] [Related]
3. Light-enhanced startle: further pharmacological and behavioral characterization.
Walker DL; Davis M
Psychopharmacology (Berl); 2002 Jan; 159(3):304-10. PubMed ID: 11862363
[TBL] [Abstract][Full Text] [Related]
4. Benzodiazepines have no effect on fear-potentiated startle in humans.
Baas JM; Grillon C; Böcker KB; Brack AA; Morgan CA; Kenemans JL; Verbaten MN
Psychopharmacology (Berl); 2002 May; 161(3):233-47. PubMed ID: 12021826
[TBL] [Abstract][Full Text] [Related]
5. Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats.
Walker DL; Davis M
Biol Psychiatry; 1997 Sep; 42(6):461-71. PubMed ID: 9285082
[TBL] [Abstract][Full Text] [Related]
6. Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.
Bijlsma EY; de Jongh R; Olivier B; Groenink L
Pharmacol Biochem Behav; 2010 Jul; 96(1):24-31. PubMed ID: 20394767
[TBL] [Abstract][Full Text] [Related]
7. Anxiogenic treatments do not increase fear-potentiated startle in mice.
Risbrough VB; Geyer MA
Biol Psychiatry; 2005 Jan; 57(1):33-43. PubMed ID: 15607298
[TBL] [Abstract][Full Text] [Related]
8. Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat.
Steiner MA; Lecourt H; Rakotoariniaina A; Jenck F
Behav Brain Res; 2011 Aug; 221(1):34-42. PubMed ID: 21354212
[TBL] [Abstract][Full Text] [Related]
9. Involvement of noradrenergic and corticoid receptors in the consolidation of the lasting anxiogenic effects of predator stress.
Adamec R; Muir C; Grimes M; Pearcey K
Behav Brain Res; 2007 May; 179(2):192-207. PubMed ID: 17335916
[TBL] [Abstract][Full Text] [Related]
10. Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety.
Walker DL; Davis M
Psychopharmacology (Berl); 2002 Nov; 164(3):318-28. PubMed ID: 12424556
[TBL] [Abstract][Full Text] [Related]
11. Fear-potentiated startle response is remarkably similar in two laboratories.
Joordens RJ; Hijzen TH; Peeters BW; Olivier B
Psychopharmacology (Berl); 1996 Jul; 126(2):104-9. PubMed ID: 8856828
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
[TBL] [Abstract][Full Text] [Related]
13. Effects of buspirone and alprazolam treatment on the startle-potentiated startle response.
Commissaris RL; Fomum EA; Leavell BJ
Depress Anxiety; 2004; 19(3):146-51. PubMed ID: 15129416
[TBL] [Abstract][Full Text] [Related]
14. The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle.
de Jongh R; Geyer MA; Olivier B; Groenink L
Behav Brain Res; 2005 Jun; 161(2):190-6. PubMed ID: 15878207
[TBL] [Abstract][Full Text] [Related]
15. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats.
Schweimer J; Fendt M; Schnitzler HU
Eur J Pharmacol; 2005 Jan; 507(1-3):117-24. PubMed ID: 15659301
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Leveleki C; Sziray N; Levay G; Barsvári B; Soproni K; Mikics E; Haller J
Brain Res Bull; 2006 Mar; 69(2):153-60. PubMed ID: 16533664
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological dissociation of moderate and high contextual fear as assessed by freezing behavior and fear-potentiated startle.
Santos JM; Gárgaro AC; Oliveira AR; Masson S; Brandão ML
Eur Neuropsychopharmacol; 2005 Mar; 15(2):239-46. PubMed ID: 15695072
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm.
Miyamoto J; Tsuji M; Takeda H; Ohzeki M; Nawa H; Matsumiya T
Eur J Pharmacol; 2004 Nov; 504(1-2):97-103. PubMed ID: 15507225
[TBL] [Abstract][Full Text] [Related]
19. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and physiological mouse models for anxiety: effects of flesinoxan in 129S6/SvEvTac and C57BL/6J mice.
Bouwknecht JA; van der Gugten J; Groenink L; Olivier B; Paylor RE
Eur J Pharmacol; 2004 Jun; 494(1):45-53. PubMed ID: 15194450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
